Venture Life Group plc (AIM:VLG)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 81.02M +17.7% |
| Revenue (ttm) | 35.17M +264.0% |
| Net Income | 6.13M +725.5% |
| EPS | 0.05 +782.5% |
| Shares Out | 121.83M |
| PE Ratio | 13.23 |
| Forward PE | 16.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 937 |
| Open | 66.00 |
| Previous Close | 66.50 |
| Day's Range | 66.00 - 67.00 |
| 52-Week Range | 50.00 - 72.00 |
| Beta | 0.23 |
| Analysts | Strong Buy |
| Price Target | 150.00 (+126.07%) |
| Earnings Date | Jun 25, 2026 |
About Venture Life Group
Venture Life Group plc develops and commercializes healthcare products in the United Kingdom. The company offers oral healthcare products, including mouthwash, toothpaste, breath freshening capsules, and dental accessories under UltraDEX and Dentyl Dual Action brands; and proctology products, such as Procto-eze Plus range for treating the discomfort caused by haemorrhoids. It also provides dermatology products comprising Myco Clear, a fungal nail cleanser and solution brand; Rosa calma for normalizing and controlling the signs and symptoms rela... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Venture Life Group Earnings Call Transcript: H2 2025
Major divestments and a shift to a brand-focused model drove 11% organic and 32% reported revenue growth, with strong cash generation and double-digit growth continuing into 2026. Power brands excelled, especially in women's and men's health, while digital transformation and innovation underpin future expansion.
Venture Life Group Quarterly report: H2 2025
Venture Life Group has published its H2 2025 quarterly earnings report on April 2, 2026.
Venture Life Group Slides: H2 2025
Venture Life Group has posted slides in relation to its H2 2025 quarterly earnings report, which was published on April 2, 2026.
Venture Life Group Earnings release: H2 2025
Venture Life Group released its H2 2025 earnings on January 26, 2026, summarizing the period's financial results.
Venture Life Group Earnings Call Transcript: H1 2025
Revenue grew 43% to £15.4m, with 12.5% organic growth and gross margin up to 43.1%. Strong cash position and divestment of non-core assets support a brand-focused, high-margin strategy, with continued investment in innovation, marketing, and M&A.
Venture Life Group Quarterly report: H1 2025
Venture Life Group has published its H1 2025 quarterly earnings report on October 1, 2025.
Venture Life Group Slides: H1 2025
Venture Life Group has posted slides in relation to its H1 2025 quarterly earnings report, which was published on October 1, 2025.
Venture Life Group Earnings release: Trading Update
Venture Life Group released its earnings on July 25, 2025, summarizing the period's financial results.
Venture Life Group Earnings Call Transcript: H2 2024
Year-end 2024 results show a strategic pivot to a capital-light, high-margin brand model, with strong growth in core segments and the Health & Her acquisition accelerating U.K. and U.S. expansion. Divestments provide cash for organic growth and M&A, with further margin gains expected.
Venture Life Group Annual report: H2 2024
Venture Life Group has published its H2 2024 annual report on July 3, 2025.
Venture Life Group Annual report: H2 2024
Venture Life Group has published its H2 2024 annual report on July 3, 2025.
Venture Life Group Slides: H2 2024
Venture Life Group has posted slides in relation to its H2 2024 quarterly earnings report, which was published on July 3, 2025.